SEC Company Response from Protara Therapeutics, Inc. (TARA) (CIK 0001359931) (TARA) — Nov 9, 2023
Protara Therapeutics, Inc. (TARA) (CIK 0001359931)
Date: Nov. 9, 2023 · CIK: 0001359931 · Accession: 0001213900-23-085377
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275290
Letter
Protara Therapeutics, Inc.
345 Park Avenue South, Third Floor
New York, NY 10010
November 9, 2023
VIA EDGAR
U.S. Securities and Exchange Commission,
Division of Corporation Finance,
Office of Life Sciences,
100 F. Street, N.E.,
Washington, D.C. 20549.
Re: Protara Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 3, 2023
File No. 333-275290
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Protara Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and declare the Registration Statement effective as of 4:00 p.m., Eastern Time, on Tuesday, November 14, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Sullivan & Cromwell LLP, requests by telephone that such Registration Statement be declared effective.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Robert W. Downes at Sullivan & Cromwell LLP at (212) 558-4312 or by email (downesr@sullcrom.com).
Very truly yours,
Protara Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Protara Therapeutics, Inc.
345 Park Avenue South, Third Floor
New York, NY 10010
November 9, 2023
VIA EDGAR
U.S. Securities and Exchange Commission,
Division of Corporation Finance,
Office of Life Sciences,
100 F. Street, N.E.,
Washington, D.C. 20549.
Re: Protara Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 3, 2023
File No. 333-275290
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Protara Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange
Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3
(the “Registration Statement”), and declare the Registration Statement effective as of 4:00 p.m., Eastern Time, on
Tuesday, November 14, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Sullivan
& Cromwell LLP, requests by telephone that such Registration Statement be declared effective.
It would be appreciated if, as soon as the Registration
Statement is declared effective, you would so inform Robert W. Downes at Sullivan & Cromwell LLP at (212) 558-4312 or by email (downesr@sullcrom.com).
Very truly yours,
Protara Therapeutics, Inc.
By:
/s/ Jesse Shefferman
Name:
Jesse Shefferman
Title:
President and Chief Executive Officer
cc:
Mary J. Grendell, General Counsel and Corporate Secretary, Protara Therapeutics, Inc.
Robert W. Downes, Sullivan & Cromwell LLP